Icon Flag ger Contact us: +49 30 230 809 - 0 

 

IGES' Portfolio for International Clients

The IGES Arzneimittel-Atlas (Drug Atlas) is a leading source of information on the German pharmaceutical market.

15 success factors for telemedicine projects

EU Guide: Reimbursement of Pharmaceuticals in the Five Largest EU Countries

15 success factors for telemedicine projects

IGES Institut acquires majority shareholding in Device Access UK

Prediabetes

Reimbursement of Medical Devices - Market Access Route

15 success factors for telemedicine projects

AiM, an IGES Group company, releases the fourth edition of the guide "Reimbursement of Medical Devices in Germany"

IGES
Life Science Team

Prof. Dr. Bertram Häussler

Chairman of the Board of Management

Fabian Berkemeier

Strategic market access consulting

Michael Branagan-Harris

Market access of medical devices

Dr. Holger Gothe

Routine data analysis

Dr. Ariane Höer

Retrospective analysis and forecasts in the SHI drug market

Wioletta Kotowa

Preparation of dossiers for the early benefit assessment

Dr. Marc Kurepkat

Clinical studies

Arrow

Dr. Tilo Mandry

Business Development International

Dr. Stephan Ruckdäschel

Health Economics & Outcomes Research

Michael Weisser

Reimbursement of medical devices

The IGES
Group

Clinical Trials

CSG (Clinical Study Group) is a full-service contract research organization, offering services in planning, implementing and analyzing clinical-scientific studies.

Arrow

Research

The IGES Institute is the core of the IGES Group. It offers comprehensive services based on advanced expertise including: studies, reports, publications, evaluations, concepts and strategies. Since its foundation, it has carried out over 2,000 research and consulting projects.

Device Access

Market Access. Accelerated

Device Access UK Ltd. is a U.K. reimbursement specialist and provides health economic and strategic services for international medical device manufacturers focused on launching products to both the U.K. private healthcare market as well as the publicly funded National Health Service (NHS).

Reimbursement Support

AiM (Assessment in Medicine) is a health economics consulting agency for the medical device industry, focusing on reimbursement programs. Health technology assessment dossiers are founded on qualitative and scientific methodologies.

Healthcare Consulting

HealthEcon, based in Basel, Switzerland is a consulting firm for health technology assessment, European market access and value strategy for the pharmaceutical industry, with almost 40 years’ experience.

IGES - The Knowledge Corporation

As an independent pioneer since 1980, the IGES Group focuses on research, development and consulting for life sciences and healthcare.

Our Expertise

From Information To Innovation: For more than 35 years we have been transforming data into valuable information in order to support numerous decisions.

Meet Us

 
 
 
 
 
 
 
 
 
 
 



A Brief History

  1. 1980+

    IGES Institute is founded as a private, independent research agency by researchers from the Berlin Institute of Technology. Its mission is to deliver expert-led research, evaluations and consultancy for decision-makers in government and administration as well as in public and private services.

  2. 1985+

    Numerous research projects are conducted on the performance of ambulatory care in Germany. IGES is a pioneer in health services research, paving the way with groundbreaking publications and providing health reporting for the German government.

  3. 1990+

    After Germany’s reunification, IGES plays a pivotal role in the process of integrating the East German healthcare system into Germany’s unified healthcare system. IGES also makes a key contribution to the development of a risk adjustment scheme for statutory sickness funds.

  4. 1995+

    IGES is a pioneer in the integration of medical care. The institute develops novel comprehensive healthcare models for patients with chronic conditions. Building on its expertise in data analysis, IGES introduces benchmarking and quality management consulting services for the healthcare sector.

  5. 2000+

    IGES increasingly turns its focus towards the pharmaceutical market. Studies on population-based utilization, market dynamics of patent protection, efficacy and efficiency figure prominently in addition to health technology assessment (HTA) and healthcare research.

  6. 2005+

    IGES is able to conduct numerous integrated projects by combining clinical research with methods used in health economics. At the same time, healthcare research becomes an increasingly important area of its work. Internationally, IGES assists several developing countries in establishing health service structures.

  7. 2010+

    Health benefit assessment for new drugs becomes mandatory in Germany. IGES responds to the growing demand by setting up a separate agency dedicated to health economics and outcomes research. As a first step towards offering its services throughout Europe, IGES expands into Switzerland.

  8. 2015+

    Benefit assessment becomes increasingly important worldwide. This will not only have an impact on drugs, but also on certain medical devices.
    IGES pools its members’ specialist expertise in theme-focused centers of competence, thus highlighting its interdisciplinary trademark.

  9. 2016

    IGES

  10. 2016

    IGES

  11. 2017

    IGES